Development of Oral Natruiretic Peptides for Congestive Heart Failure

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1017672

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Congestive heart failure is fatal disease and a major disease burden for the community affecting nearly half a million Australians. Current therapies are inadequate. We seek to develop a new peptide therapy based on snake venom version of the human B type natriuretic peptide which has to be given by injection. We will produce an orally active, stable and effective treatment using a program of discovery involving testing in animals and cells.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Development Grants

Funding Amount: $511,037.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cardiovascular pharmacology | drug development | heart disease | heart failure | natriuretic peptides

Related Links